Market Overview

UPDATE: Jefferies Raises PT on Becton, Dickinson and Co. on Compelling Secular Growth Story

Share:
Related BDX
Benzinga's Top Upgrades
UBS Upgrades Becton Dickinson To Buy
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

In a report published Thursday, Jefferies analyst Jon Wood reiterated a Buy rating on Becton, Dickinson and Co. (NYSE: BDX), and raised the price target from $96.00 to $107.00.

In the report, Wood noted, “BDX's foray into the generic prefilled injectable drug arena adds a new compelling secular growth story to the investment thesis. With its main competitor enduring chronic manufacturing / QC issues, BDX's ability to leverage its hospital channel presence should help stimulate initial uptake. We are raising our FY14 EPS forecast to $6.25 (from $6.20). Our PT moves to $107 (from $96) on higher intermediate-term cash flow forecasts.”

Becton, Dickinson and Co. closed on Wednesday at $95.16.

Latest Ratings for BDX

DateFirmActionFromTo
Jul 2015BarclaysReinstatesEqual-weight
Jun 2015UBSUpgradesBuy
Mar 2015Goldman SachsReinstatesNeutral

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BDX)

Get Benzinga's Newsletters